Retraction: Identifying the inhibitory mechanism of apigenin on the insulin ligand–receptor binding

Yong Yang

doi:10.1039/C6MD90032A

View PDF VersionPrevious ArticleNext Article

Open Access Article

This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

DOI: 10.1039/C6MD90032A (Retraction) Med. Chem. Commun., 2016, 7, 1449-1449

Retraction: Identifying the inhibitory mechanism of apigenin on the insulin ligand–receptor binding

Yong Yang *
Institute of Metabolic Disease Research and Drug Development, China Medical University, Shenyang, Liaoning 110001, People's Republic of China. E-mail: yyang@mail.cmu.edu.cn; Tel: +86 18900911994

Received 20th June 2016 , Accepted 20th June 2016

First published on 27th June 2016

Abstract

Retraction of ‘Identifying the inhibitory mechanism of apigenin on the insulin ligand–receptor binding’ by Yong Yang, Med. Chem. Commun., 2015, 6, 1190–1195.

I, the named author, hereby wholly retract this MedChemComm article due to extensive text and data overlap with a previous publication that I co-authored.¹

Fig. 1b–d, 2b–d, 3a and 3b in this MedChemComm paper were copied from ref. 1 and do not represent results from experiments with apigenin.

This retraction supersedes the information provided in the Expression of Concern related to this article.

Signed: Yong Yang, 22nd June 2016.

Retraction endorsed by Richard Kelly, Executive Editor, MedChemComm.

1. Quercetin suppresses insulin receptor signaling through inhibition of the insulin ligand–receptor binding and therefore impairs cancer cell proliferation, Feng Wang and Yong Yang, Biochem. Biophys. Res. Commun., 2014, 452, 1028–1033.